Company intelligence / Profile preview

Embera NeuroTherapeutics

Sudbury, Massachusetts, United Statesemberaneuro.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

EMB-001 was well-tolerated in Phase 1 and Phase 1b cocaine interaction studies with no new safety signals observed. The company has completed Series B financing and received grants to advance EMB-001 into Phase 2 clinical studies for cocaine use disorder and smoking cessation. Phase 2 studies began dosing subjects in Q1 2020.

Therapeutic areas: Psychiatry
Modalities: Small moleculesDrug combinations
Industry: Biotech

Drug pipeline

1 asset

EMB-001

Phase 2

Indications: Cocaine use disorder, Smoking cessation

Partnerships

National Institute on Drug Abuse (NIDA)Rose Research Center (RRC)Foundation for a Smoke-Free World

Beyond the preview

Go deeper on Embera NeuroTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Embera NeuroTherapeutics.

Explore the full profile